Boehringer Ingelheim Announces Interim Results on Adalimumab Biosimilar Candidate BI695501

Goodwin
Contact
LinkedIn
Facebook
X
Send
Embed

Boehringer Ingelheim announced the 24-week results from the Phase III VOLTAIRE®-RA study, comparing the adalimumab biosimilar candidate BI 695501 to Abbvie’s Humira® in patients with moderate- to severely-active rheumatoid arthritis.  According to BI, the results indicate that BI 695501 has similar efficacy, safety, and immunogenicity as Humira® in these patients.  The results will be presented at the Annual European Congress of Rheumatology (EULAR 2017) in Madrid.

Send Print Report

DISCLAIMER: Because of the generality of this update, the information provided herein may not be applicable in all situations and should not be acted upon without specific legal advice based on particular situations.

© Goodwin | Attorney Advertising

Written by:

Goodwin
Goodwin
Contact
more
less

Goodwin on:

Reporters on Deadline

"My best business intelligence, in one easy email…"

Your first step to building a free, personalized, morning email brief covering pertinent authors and topics on JD Supra:
Sign Up Log in
*By using the service, you signify your acceptance of JD Supra's Privacy Policy.
Custom Email Digest
- hide
- hide